Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Wallace, R. J.    Brown, B. A.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Clinical Trial of Clarithromycin for Cutaneous (Disseminated) Infection due to Mycobacterium chelonae

Richard J. Wallace; David Tanner; Patrick J. Brennan; and Barbara A. Brown

15 September 1993 | Volume 119 Issue 6 | Pages 482-486

Objective: To determine if clarithromycin monotherapy is safe and effective in treating cutaneous disease (especially disseminated disease) due to Mycobacterium chelonae (formerly M. chelonae subspecies chelonae).

Design: An open, noncomparative trial of clarithromycin as single-drug therapy.

Setting: Nationwide referrals.

Patients: Culture-positive patients whose M. chelonae came from a cutaneous source and whose isolate was submitted to a single referral laboratory for susceptibility testing.

Intervention: Clarithromycin, 500 mg twice a day by mouth for 6 months. No attempt was made to alter use of immunosuppressive drugs.

Main Outcome Measures: Acid-fast bacilli smears and cultures of skin lesions during and after treatment, with monitoring of clinical response, side effects, and development of new lesions.

Results: Fourteen patients (10 with disseminated disease) were enrolled in the study and completed at least 3 months of therapy. Underlying diseases included rheumatoid arthritis, other autoimmune disorders, and organ transplantation. All were taking corticosteroids (93%) or cyclophosphamide (7%). All patients had an excellent response to therapy, with only mild side effects from the drug. Two patients died of other diseases after improving clinically but while still taking medication. One noncompliant patient who prematurely discontinued therapy after 3.5 months relapsed 1 month later with an isolate resistant to clarithromycin. The remaining 11 patients have all completed therapy given for a mean of 6.8 months (range, 4.5 to 9 months). Therapy has been discontinued for 9 of the 11 patients for at least 6 months (mean, 7.1 months; range, 6 to 12 months), with no evidence of relapse. No remaining patient had positive acid-fast bacilli smears or cultures of skin lesions after 1 month of therapy.

Conclusions: Clarithromycin may be the drug of choice for cutaneous (disseminated) disease due to M. chelonae, although more patients with long-term clinical follow-up need to be studied.

Author and Article Information

From the University of Texas Health Center at Tyler, Tyler, Texas; Duke University Medical Center, Durham, North Carolina; the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Requests for Reprints: Richard J. Wallace, Jr., MD, Department of Microbiology, The University of Texas Health Center, P.O. Box 2003, Tyler, TX 75710.
Acknowledgments: The authors thank Richard Drew for administrative help and the following physicians who allowed the authors to help follow their patients: John Dunkel, Huntsville, Alabama; Audrey French, Burlington, Vermont; Beverly Alston, Chapel Hill, North Carolina; Charles Bryan, Columbia, South Carolina; Clay Dunagan, St. Louis, Missouri; Judith Schlay, Denver, Colorado; Steve Dummer, Nashville, Tennessee; John Ladd, Corvallis, Oregon; and Mary Aspen, Orange, California.
Grant Support: In part by a grant from Abbott Laboratories, Chicago, Illinois.

This article has been cited by other articles:

				H.-C. Hsieh, P.-L. Lu, T.-C. Chen, K. Chang, and Y.-H. Chen Mycobacterium chelonae empyema in an immunocompetent patient J. Med. Microbiol., May 1, 2008; 57(5): 664 - 667. [Abstract] [Full Text] [PDF]

				D. E. Griffith, T. Aksamit, B. A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, S. M. Holland, R. Horsburgh, G. Huitt, M. F. Iademarco, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases Am. J. Respir. Crit. Care Med., February 15, 2007; 175(4): 367 - 416. [Full Text] [PDF]

				M Dungarwalla, A Field-Smith, C Jameson, U Riley, A Chapman, C. Bunker, C. Dearden, and E Matutes Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia Haematologica, January 1, 2007; 92(1): e5 - e6. [Full Text] [PDF]

				D. Z. Uslan, T. J. Kowalski, N. L. Wengenack, A. Virk, and J. W. Wilson Skin and Soft Tissue Infections Due to Rapidly Growing Mycobacteria: Comparison of Clinical Features, Treatment, and Susceptibility. Arch Dermatol, October 1, 2006; 142(10): 1287 - 1292. [Abstract] [Full Text] [PDF]

				A. Scholze, C. Loddenkemper, M. Grunbaum, I. Moosmayer, G. Offermann, and M. Tepel Cutaneous Mycobacterium abscessus infection after kidney transplantation Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1764 - 1765. [Full Text] [PDF]

				B. A. Brown-Elliott and R. J. Wallace Jr. Clinical and Taxonomic Status of Pathogenic Nonpigmented or Late-Pigmenting Rapidly Growing Mycobacteria Clin. Microbiol. Rev., October 1, 2002; 15(4): 716 - 746. [Abstract] [Full Text] [PDF]

				A. Aubry, O. Chosidow, E. Caumes, J. Robert, and E. Cambau Sixty-three Cases of Mycobacterium marinum Infection: Clinical Features, Treatment, and Antibiotic Susceptibility of Causative Isolates Arch Intern Med, August 12, 2002; 162(15): 1746 - 1752. [Abstract] [Full Text] [PDF]

				M.-M. Gordon, H. E. Wilson, F. R. Duthie, B. Jones, and M. Field When typical is atypical: mycobacterial infection mimicking cutaneous vasculitis Rheumatology, June 1, 2002; 41(6): 685 - 690. [Abstract] [Full Text] [PDF]

				B. A. Brown-Elliott, R. J. Wallace Jr., M. Sanguinetti, and G. Fadda Clarithromycin Resistance in Mycobacterium abscessus J. Clin. Microbiol., July 1, 2001; 39(7): 2745 - 2746. [Full Text] [PDF]

				A. Aubry, V. Jarlier, S. Escolano, C. Truffot-Pernot, and E. Cambau Antibiotic Susceptibility Pattern of Mycobacterium marinum Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3133 - 3136. [Abstract] [Full Text]

				J. Murillo, J. Torres, L. Bofill, A. Rios-Fabra, E. Irausquin, R. Isturiz, M. Guzman, J. Castro, L. Rubino, M. Cordido, et al. Skin and Wound Infection by Rapidly Growing Mycobacteria: An Unexpected Complication of Liposuction and Liposculpture Arch Dermatol, November 1, 2000; 136(11): 1347 - 1352. [Abstract] [Full Text] [PDF]

				Subcommittee of the Joint Tuberculosis Committee o Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999 Thorax, March 1, 2000; 55(3): 210 - 218. [Full Text]

				R. J. Wallace Jr., B. A. Brown;, P.-R. Hsueh, and K.-T. Luh Catheter Sepsis Due to Mycobacterium chelonae J. Clin. Microbiol., November 1, 1998; 36(11): 3444 - 3445. [Full Text]

				F. Portaels, H. Traore, K. De Ridder, and W. M. Meyers In Vitro Susceptibility of Mycobacterium ulcerans to Clarithromycin Antimicrob. Agents Chemother., August 1, 1998; 42(8): 2070 - 2073. [Abstract] [Full Text]

				Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 1 - 25. [Full Text]